<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements</h1>

    <table>
      <tr><th>Ticker</th><td>ASBP</td></tr>
      <tr><th>Float</th><td>3.1 M</td></tr>
      <tr><th>IO</th><td>4.00%</td></tr>
      <tr><th>MC</th><td>4.9 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Aspire Biopharma (NASDAQ: ASBP) entered a securities purchase agreement on Feb 6, 2026 to sell up to 26,250 shares of Series A Convertible Preferred Stock at $800 each for aggregate gross proceeds up to $21.0 million. The company completed an initial closing on Feb 6, issuing 13,750 preferred shares for $11.0 million gross; proceeds will be used to repay legacy indebtedness, support operations, fund strategic initiatives and pay offering expenses. The offering is intended to help Aspire regain compliance with Nasdaq stockholders' equity listing requirements and strengthen its balance sheet; a second closing is expected but remains subject to customary conditions. RBW Capital Partners LLC acted as sole placement agent, and the company filed a Form 8-K disclosing the transaction and intends to file registration statements covering resale of shares issuable upon conversion.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Initial closing raised $11.0 million in gross proceeds with up to $21.0 million available, improving near-term liquidity.</li><li>Proceeds earmarked to reduce outstanding indebtedness, which should improve balance sheet and financial flexibility.</li><li>Transaction intended to help the company regain compliance with Nasdaq stockholders' equity listing requirements.</li><li>Placement agent engaged (RBW Capital Partners LLC) and the company committed to file resale registration for converted shares.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Preferred shares are convertible into common stock, which will dilute existing common shareholders upon conversion.</li><li>Securities were issued in an unregistered private placement and resale is restricted until registration statements are effective.</li><li>Second closing for the remainder of the offering is conditional and not guaranteed, leaving completion risk for the full $21.0 million.</li><li>Use of proceeds to cover legacy indebtedness and operating needs indicates prior cash/solvency pressure and ongoing financing dependence.</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/fae883b7-f414-4d4a-9b48-a8aaca9724a8" target="_blank">Original Article</a>
    </div>

    <div class="small">ASBP â€¢ TradersLink AI News</div>
  </div>
</body>
</html>